Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.

Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, Petoumenos K, Zang G, Shaw I, Yeung B, George J, Teutsch S, Kaldor JM, Cherepanov V, Bruneau J, Shoukry NH, Lloyd AR, Dore GJ.

Hepatology. 2013 Jun;57(6):2124-34. doi: 10.1002/hep.26263. Epub 2013 May 8.

2.

Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.

Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, Scherzer TM, Strassl R, Bischof M, Stauber R, Bodlaj G, Laferl H, Holzmann H, Steindl-Munda P, Ferenci P, Hofer H.

Gastroenterology. 2012 Jan;142(1):78-85.e2. doi: 10.1053/j.gastro.2011.09.039. Epub 2011 Sep 24.

PMID:
22192885
3.

A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection.

Beinhardt S, Payer BA, Datz C, Strasser M, Maieron A, Dorn L, Grilnberger-Franz E, Dulic-Lakovic E, Stauber R, Laferl H, Aberle JH, Holzmann H, Krall C, Vogel W, Ferenci P, Hofer H.

J Hepatol. 2013 Nov;59(5):972-7. doi: 10.1016/j.jhep.2013.06.028. Epub 2013 Jul 10.

PMID:
23850880
4.

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.

Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups.

Hepatology. 2010 May;51(5):1523-30. doi: 10.1002/hep.23509.

PMID:
20186843
5.

Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.

Al-Ashgar HI, Khan MQ, Helmy A, Al-Thawadi S, Al-Ahdal MN, Khalaf N, Al-Qahtani A, Sanai FM.

Eur J Gastroenterol Hepatol. 2013 Apr;25(4):404-10. doi: 10.1097/MEG.0b013e32835bc2cf.

PMID:
23470264
6.

IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.

Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, Gangl A, Holzmann H, Peck-Radosavljevic M.

Antivir Ther. 2008;13(8):969-76.

PMID:
19195322
7.

Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution.

Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC.

Hepatology. 2012 Jun;55(6):1684-91. doi: 10.1002/hep.25575. Epub 2012 Apr 18.

8.

IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV.

Falconer K, Askarieh G, Weis N, Hellstrand K, Alaeus A, Lagging M.

Scand J Infect Dis. 2010 Dec;42(11-12):896-901. doi: 10.3109/00365548.2010.498019. Epub 2010 Jul 7.

PMID:
20608766
9.

Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.

Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Dore GJ, Grebely J; InC3 Study Group.

PLoS One. 2015 Apr 2;10(4):e0122232. doi: 10.1371/journal.pone.0122232. eCollection 2015.

10.

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.

Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR, Booth D, Kaldor JM, George J, Dore GJ; ATAHC Study Group.

Hepatology. 2010 Oct;52(4):1216-24. doi: 10.1002/hep.23850.

11.

Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC(3)Study Group.

J Clin Virol. 2014 Nov;61(3):430-4. doi: 10.1016/j.jcv.2014.08.027. Epub 2014 Sep 8.

12.

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.

Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K; DITTO-HCV Study Group.

PLoS One. 2011 Feb 24;6(2):e17232. doi: 10.1371/journal.pone.0017232.

13.

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; ITAHEC Study Group.

Aliment Pharmacol Ther. 2011 May;33(10):1162-72. doi: 10.1111/j.1365-2036.2011.04635.x. Epub 2011 Mar 28.

14.

The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10.

Qu J, Zhang Q, Li Y, Liu W, Chen L, Zhu Y, Wu J.

BMC Immunol. 2012 Apr 3;13:15. doi: 10.1186/1471-2172-13-15.

15.

Correlates of spontaneous clearance of hepatitis C virus in a Danish human immunodeficiency virus type 1 cohort.

Clausen LN, Weis N, Schønning K, Fenger M, Krarup H, Bukh J, Benfield T.

Scand J Infect Dis. 2011 Oct;43(10):798-803. doi: 10.3109/00365548.2011.589077. Epub 2011 Jul 5.

PMID:
21728744
16.

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.

Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, Shianna KV, Afdhal NH, Hudson ML, Howell CD, Talloen W, Bollekens J, De Wit M, Scholliers A, Fried MW.

Hepatology. 2011 Jan;53(1):14-22. doi: 10.1002/hep.24056.

17.

Dynamics of HCV RNA levels during acute hepatitis C virus infection.

Hajarizadeh B, Grebely J, Applegate T, Matthews GV, Amin J, Petoumenos K, Hellard M, Rawlinson W, Lloyd A, Kaldor J, Dore GJ; ATAHC study group.

J Med Virol. 2014 Oct;86(10):1722-9. doi: 10.1002/jmv.24010. Epub 2014 Jul 8.

18.

Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients.

Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):262-8.

PMID:
17414926
19.

The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection.

Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M; InC3 Study Group.

Hepatology. 2014 Jan;59(1):109-20. doi: 10.1002/hep.26639. Epub 2013 Nov 22.

20.

High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.

Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H.

J Med Virol. 2004 Jul;73(3):387-91.

PMID:
15170633
Items per page

Supplemental Content

Write to the Help Desk